Cardiac Function in Patients With Hereditary Hemochromatosis
NCT ID: NCT00068159
Last Updated: 2024-05-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
70 participants
Study Classification
OBSERVATIONAL
Study Start Date
2003-12-08
Study Completion Date
2022-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will examine the effect of iron buildup in the hearts of patients with hereditary hemochromatosis (HH), a genetic disease that causes the body to accumulate excess amounts of iron. The excess iron can damage the heart, liver, pancreas, skin, and joints. Generally, early treatment with phlebotomy (periodic removal of a unit of blood), and in some cases chelation (using a drug to remove iron from the body) slows down organ damage in HH patients. This study will try to elucidate the effect of iron buildup in the heart and determine if phlebotomy and chelation help keep the heart healthy.
Patients with HH and healthy volunteers 21 years of age and older may be eligible for this study. (Normal volunteers will provide normal values of heart function that will be used to verify abnormalities detected in HH patients.) Patients must have a gene abnormality of Hfe gene Cys282Try homozygote. They may or may not be receiving treatment for HH and they must have no heart symptoms or serious organ damage due to HH. Candidates will be screened with a medical history and physical examination, blood tests, electrocardiogram (EKG), Holter EKG (24-hour EKG monitoring, see description below), and chest x-ray.
Participants will undergo the following tests and procedures over 2 to 5 days:
* Exercise test: The participant exercises on a treadmill while wearing a mouthpiece, which is used to measure how much oxygen is used. Electrodes placed on the chest and arms monitor the heartbeat during the test.
* Echocardiography: This ultrasound test uses sound waves to take pictures. A small probe is held against the chest to allow a technician to take pictures of the heart and assess its function. A drug called Optison may be injected in an arm vein if needed to enhance the ultrasound images.
* Exercise stress echocardiography: The participant exercises on a stationary bike while heart function is measured with an echocardiogram, EKG, and blood pressure cuff.
* 24-hour Holter EKG: The participant wears a small machine that records heart rhythm continuously for 24 hours. The recorder is connected by cables to electrodes placed on the chest.
* Magnetic resonance imaging: This test uses a magnetic field and radio waves to obtain detailed images of the heart and blood vessels. The participant lies flat on a table that slides inside the scanner, which is a large hollow tube.
All tests are performed once in normal volunteers and in patients who have received standard treatment for HH. Untreated patients repeat the tests 6 months after beginning phlebotomy or chelation. Additional time points for these tests might be added if further evaluation is needed.
Patients with HH and healthy volunteers 21 years of age and older may be eligible for this study. (Normal volunteers will provide normal values of heart function that will be used to verify abnormalities detected in HH patients.) Patients must have a gene abnormality of Hfe gene Cys282Try homozygote. They may or may not be receiving treatment for HH and they must have no heart symptoms or serious organ damage due to HH. Candidates will be screened with a medical history and physical examination, blood tests, electrocardiogram (EKG), Holter EKG (24-hour EKG monitoring, see description below), and chest x-ray.
Participants will undergo the following tests and procedures over 2 to 5 days:
* Exercise test: The participant exercises on a treadmill while wearing a mouthpiece, which is used to measure how much oxygen is used. Electrodes placed on the chest and arms monitor the heartbeat during the test.
* Echocardiography: This ultrasound test uses sound waves to take pictures. A small probe is held against the chest to allow a technician to take pictures of the heart and assess its function. A drug called Optison may be injected in an arm vein if needed to enhance the ultrasound images.
* Exercise stress echocardiography: The participant exercises on a stationary bike while heart function is measured with an echocardiogram, EKG, and blood pressure cuff.
* 24-hour Holter EKG: The participant wears a small machine that records heart rhythm continuously for 24 hours. The recorder is connected by cables to electrodes placed on the chest.
* Magnetic resonance imaging: This test uses a magnetic field and radio waves to obtain detailed images of the heart and blood vessels. The participant lies flat on a table that slides inside the scanner, which is a large hollow tube.
All tests are performed once in normal volunteers and in patients who have received standard treatment for HH. Untreated patients repeat the tests 6 months after beginning phlebotomy or chelation. Additional time points for these tests might be added if further evaluation is needed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Hemochromatosis
NCT00007150
Hemochromatosis
ACTIVE_NOT_RECRUITING
PHASE2
Hemochromatosis--Genetic Prevalence and Penetrance
NCT00006312
Blood Disease
Hemochromatosis
COMPLETED
Deferoxamine for the Treatment of Hemochromatosis
NCT00001203
Diabetes Mellitus
Heart Disease
Hemochromatosis
+1 more
COMPLETED
Statistical Basis for Hemochromatosis Screening
NCT00005559
Blood Disease
Hemochromatosis
COMPLETED
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595
Anemia (Iron-Loading)
Beta-Thalassemia
Hematologic Diseases
+4 more
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hereditary hemochromatosis (HH) is the most common hereditary metabolic abnormality among Caucasians. Homozygosity for the Cys282Tyr mutation, which is the most common known mutation with a predisposition to iron overload, occurs with an estimated frequency of 8 per 1000 in the Caucasians. Hemochromatosis in its advanced stages is associated with severe cardiac complications including congestive heart failure, premature coronary artery disease, and cardiac arrhythmias. The clinical manifestations of HH are due to increased iron absorption and abnormal iron cycling with excessive iron deposition in various organs. Mutations of the Hfe gene on chromosome 6 have been recently identified. Although the pathophysiology remains incompletely understood, a homozygote mutation in Cys282Tyr is present in 84 to 100% of clinically confirmed HH cases. This discovery permits the early diagnosis of this disease and could be used for screening to identify asymptomatic cases. Therefore, the NHLBI in January 2000 launched a 30 million dollar project named HEIRS (HEmochromatosis and IRon overload Study) to screen 1,000,000 adults for HH, and recently completed enrollment.
\<TAB\>
Increased left ventricular wall thickness and mass has been found to be early cardiac manifestations of HH appearing before the onset of contractile dysfunction. Interestingly, a report also indicates that functional abnormalities of the heart can be seen in predominantly asymptomatic HH patient group. Such abnormalities of diastolic function are detected by Doppler echocardiography. Observations support the theory that asymptomatic cardiac dysfunction is detectable with non-invasive cardiac imaging in patients with HH. \<TAB\>
\<TAB\>
Although the pathophysiology of cardiac dysfunction in HH has not been well characterized, it is speculated that enhanced production of reactive oxygen species (ROS) may be responsible for tissue damage. Therefore, biochemical and/or genetic markers of oxidant stress might be helpful in determining whether this mechanism is involved in producing cardiac dysfunction.
In this protocol, we propose a retrospective pilot study with a small-sized nested prospective study of cardiac function in patients with HH. The intention is to utilize obtained results to design a larger definitive study if results are warranted. The following hypotheses will be tested: Cardiac abnormalities 1) can be diagnosed with conventional non-invasive cardiac imaging in HH patients with New York Heart Association Functional Class I (asymptomatic), 2) limit patients' exercise capacity, 3) are associated with an elevated oxidant stress level, and 4) are improved by phlebotomy and its efficacy correlated with a reduction in oxidant stress.
\<TAB\>
Increased left ventricular wall thickness and mass has been found to be early cardiac manifestations of HH appearing before the onset of contractile dysfunction. Interestingly, a report also indicates that functional abnormalities of the heart can be seen in predominantly asymptomatic HH patient group. Such abnormalities of diastolic function are detected by Doppler echocardiography. Observations support the theory that asymptomatic cardiac dysfunction is detectable with non-invasive cardiac imaging in patients with HH. \<TAB\>
\<TAB\>
Although the pathophysiology of cardiac dysfunction in HH has not been well characterized, it is speculated that enhanced production of reactive oxygen species (ROS) may be responsible for tissue damage. Therefore, biochemical and/or genetic markers of oxidant stress might be helpful in determining whether this mechanism is involved in producing cardiac dysfunction.
In this protocol, we propose a retrospective pilot study with a small-sized nested prospective study of cardiac function in patients with HH. The intention is to utilize obtained results to design a larger definitive study if results are warranted. The following hypotheses will be tested: Cardiac abnormalities 1) can be diagnosed with conventional non-invasive cardiac imaging in HH patients with New York Heart Association Functional Class I (asymptomatic), 2) limit patients' exercise capacity, 3) are associated with an elevated oxidant stress level, and 4) are improved by phlebotomy and its efficacy correlated with a reduction in oxidant stress.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hereditary Hemochromatosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Untreated-NYHA Class I HH subjects without conventional therapy for HH
No interventions assigned to this group
2
Treated- NYHA Class I HH subjects with conventional phlebotomy and/or iron chelation therapy
No interventions assigned to this group
3
Age-gender matched healthy HH control volunteers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
HH Patients
Group A patients (untreated HH patients)
Adults 21 years or older
New York Heart Association Functional Classification Class I
Documented positive phenotyping for homozygote Cys282Tyr of Hfe gene with documented serum ferritin level above 400 ng/ml or documented % iron saturation more than 60%.
Patient has not received standard chronic phlebotomy or deferoxamine treatment. Individuals are allowed to have up to 3 emergency phlebotomies for alleviation of severe iron accumulation before enrollment.
Group B patients (treated HH patients)
Adults 21 years or older
New York Heart Association Functional Classification Class I
Documented positive phenotyping for homozygote Cys282Tyr of Hfe gene with documented serum ferritin level above 400 ng/ml or documented % iron saturation more than 60%.
Patient has been compliant with standard phlebotomy and/or deferoxamine treatment for 6 months or longer and in stable phase with iron saturation 50% or less.
Healthy Volunteers
Group C Patients (Age-Gender Matched Healthy Control Subjects)
Adults 21 years or older.
No symptoms suggestive of heart disease or any other medical conditions, negative Hfe genotyping for Cys282Tyr or His63Asp with normal ferritin and iron saturation.
Group A patients (untreated HH patients)
Adults 21 years or older
New York Heart Association Functional Classification Class I
Documented positive phenotyping for homozygote Cys282Tyr of Hfe gene with documented serum ferritin level above 400 ng/ml or documented % iron saturation more than 60%.
Patient has not received standard chronic phlebotomy or deferoxamine treatment. Individuals are allowed to have up to 3 emergency phlebotomies for alleviation of severe iron accumulation before enrollment.
Group B patients (treated HH patients)
Adults 21 years or older
New York Heart Association Functional Classification Class I
Documented positive phenotyping for homozygote Cys282Tyr of Hfe gene with documented serum ferritin level above 400 ng/ml or documented % iron saturation more than 60%.
Patient has been compliant with standard phlebotomy and/or deferoxamine treatment for 6 months or longer and in stable phase with iron saturation 50% or less.
Healthy Volunteers
Group C Patients (Age-Gender Matched Healthy Control Subjects)
Adults 21 years or older.
No symptoms suggestive of heart disease or any other medical conditions, negative Hfe genotyping for Cys282Tyr or His63Asp with normal ferritin and iron saturation.
Exclusion Criteria
HH patients
Group A patients (untreated HH patients)
Pregnant or lactating women
History or present evidence of coronary artery disease, heart failure, peripheral vascular disease, coagulopathy, or uncontrolled hypertension (systolic blood pressure over 170 mmHg and/or diastolic pressure over 100 mmHg).
History of significant end-organ damage secondary to HH.
Serum creatinine greater than 2.0 mg/ml
LFT's more than 2.5 times above upper limit of normal
History of structural cardiac disease except mitral valve prolapse with mild mitral regurgitation
Uncontrolled glucose levels with hemoglobin A(1c) above 8 mg/dl or the use of more than one oral hyperglycemic agents or insulin therapy to control diabetes.
Current use of antioxidant treatment such as vitamin E and C. However, the cessation of this treatment 4 weeks prior to the study will allow for inclusion.
Evidence of impaired immunity including HIV
Chronic systemic inflammatory disease such as SLE, rheumatoid arthritis, collagen vascular disease.
Participation in unrelated research involving investigational pharmacological agent in past 30 days.
Current alcohol use (more than 26 grams averaged ethanol intake per day) or drug abuse.
Inability to provide informed consent
Smoking in past 3 months.
Use of beta-adrenergic blocking agents and calcium channel blockers with negative chronotropic effect within 1 week.
Inability to perform treadmill or bicycle exercise testing.
Inability to undergo MRI such as ferromagnetic implant.
Group B patients (treated HH patients)
Pregnant or lactating women
History or present evidence of coronary artery disease, heart failure, peripheral vascular disease, coagulopathy, or uncontrolled hypertension (systolic blood pressure over 170 mmHg and/or diastolic pressure over 100 mmHg).
History of significant end-organ damage secondary to HH.
Serum creatinine greater than 2.0 mg/ml
LFT's more than 2.5 times above upper limit of normal
History of structural cardiac disease except mitral valve prolapse with mild mitral regurgitation
Uncontrolled glucose levels with hemoglobin A(1c) above 8 mg/dl or the use of more than one oral hyperglycemic agents or insulin therapy to control diabetes.
Current use of antioxidant treatment such as vitamin E and C. However, the cessation of this treatment 4 weeks prior to the study will allow for inclusion.
Evidence of impaired immunity including HIV
Chronic systemic inflammatory disease such as SLE, rheumatoid arthritis, collagen vascular disease.
Participation in unrelated research involving investigational pharmacological agent in past 30 days.
Current alcohol use (more than 26 grams averaged ethanol intake per day) or drug abuse.
Inability to provide informed consent
Smoking in past 3 months.
Use of beta-adrenergic blocking agents and calcium channel blockers with negative chronotropic effect within 1 week.
Inability to perform treadmill or bicycle exercise testing.
Inability to undergo MRI such as ferromagnetic implant.
Healthy volunteers
Group C Patients (Age-Gender Matched Healthy Control Subjects)
Pregnant or lactating women.
History or present evidence of any structural cardiac disease except mitral valve prolapse with mild mitral regurgitation, heart failure, peripheral vascular disease, coagulopathy, and uncontrolled hypertension (systolic blood pressure over 170 mmHg and/or diastolic pressure over 100 mmHg).
Serum creatinine greater than 2.0 mg/ml.
LFT's more than 2.5 times above upper limit of normal.
Current use of antioxidant treatment such as vitamin E and C. However, the cessation of this treatment 4 weeks prior to the study will be included.
Uncontrolled glucose levels with hemoglobin A(1C) above 8 mg/dl or the use of oral hyperglycemic agents or insulin therapy to control diabetes.
Evidence of impaired immunity including HIV.
Chronic systemic inflammatory disease such as SLE, rheumatoid arthritis, collagen vascular disease.
Participation in unrelated research involving investigational pharmacological agent in past 30 days.
Current alcohol use (more than 26 grams averaged ethanol intake per day) or drug abuse.
Inability to provide informed consent.
Smoking in past 3 months.
Subjects with any chronic medical problems\*
Inability to undergo MRI such as ferromagnetic implant.
\*For the purpose of this protocol "chronic medical problems' is defined as any current condition not amenable to curative therapy and which requires long-term medical treatment and/or clinical monitoring.
Group A patients (untreated HH patients)
Pregnant or lactating women
History or present evidence of coronary artery disease, heart failure, peripheral vascular disease, coagulopathy, or uncontrolled hypertension (systolic blood pressure over 170 mmHg and/or diastolic pressure over 100 mmHg).
History of significant end-organ damage secondary to HH.
Serum creatinine greater than 2.0 mg/ml
LFT's more than 2.5 times above upper limit of normal
History of structural cardiac disease except mitral valve prolapse with mild mitral regurgitation
Uncontrolled glucose levels with hemoglobin A(1c) above 8 mg/dl or the use of more than one oral hyperglycemic agents or insulin therapy to control diabetes.
Current use of antioxidant treatment such as vitamin E and C. However, the cessation of this treatment 4 weeks prior to the study will allow for inclusion.
Evidence of impaired immunity including HIV
Chronic systemic inflammatory disease such as SLE, rheumatoid arthritis, collagen vascular disease.
Participation in unrelated research involving investigational pharmacological agent in past 30 days.
Current alcohol use (more than 26 grams averaged ethanol intake per day) or drug abuse.
Inability to provide informed consent
Smoking in past 3 months.
Use of beta-adrenergic blocking agents and calcium channel blockers with negative chronotropic effect within 1 week.
Inability to perform treadmill or bicycle exercise testing.
Inability to undergo MRI such as ferromagnetic implant.
Group B patients (treated HH patients)
Pregnant or lactating women
History or present evidence of coronary artery disease, heart failure, peripheral vascular disease, coagulopathy, or uncontrolled hypertension (systolic blood pressure over 170 mmHg and/or diastolic pressure over 100 mmHg).
History of significant end-organ damage secondary to HH.
Serum creatinine greater than 2.0 mg/ml
LFT's more than 2.5 times above upper limit of normal
History of structural cardiac disease except mitral valve prolapse with mild mitral regurgitation
Uncontrolled glucose levels with hemoglobin A(1c) above 8 mg/dl or the use of more than one oral hyperglycemic agents or insulin therapy to control diabetes.
Current use of antioxidant treatment such as vitamin E and C. However, the cessation of this treatment 4 weeks prior to the study will allow for inclusion.
Evidence of impaired immunity including HIV
Chronic systemic inflammatory disease such as SLE, rheumatoid arthritis, collagen vascular disease.
Participation in unrelated research involving investigational pharmacological agent in past 30 days.
Current alcohol use (more than 26 grams averaged ethanol intake per day) or drug abuse.
Inability to provide informed consent
Smoking in past 3 months.
Use of beta-adrenergic blocking agents and calcium channel blockers with negative chronotropic effect within 1 week.
Inability to perform treadmill or bicycle exercise testing.
Inability to undergo MRI such as ferromagnetic implant.
Healthy volunteers
Group C Patients (Age-Gender Matched Healthy Control Subjects)
Pregnant or lactating women.
History or present evidence of any structural cardiac disease except mitral valve prolapse with mild mitral regurgitation, heart failure, peripheral vascular disease, coagulopathy, and uncontrolled hypertension (systolic blood pressure over 170 mmHg and/or diastolic pressure over 100 mmHg).
Serum creatinine greater than 2.0 mg/ml.
LFT's more than 2.5 times above upper limit of normal.
Current use of antioxidant treatment such as vitamin E and C. However, the cessation of this treatment 4 weeks prior to the study will be included.
Uncontrolled glucose levels with hemoglobin A(1C) above 8 mg/dl or the use of oral hyperglycemic agents or insulin therapy to control diabetes.
Evidence of impaired immunity including HIV.
Chronic systemic inflammatory disease such as SLE, rheumatoid arthritis, collagen vascular disease.
Participation in unrelated research involving investigational pharmacological agent in past 30 days.
Current alcohol use (more than 26 grams averaged ethanol intake per day) or drug abuse.
Inability to provide informed consent.
Smoking in past 3 months.
Subjects with any chronic medical problems\*
Inability to undergo MRI such as ferromagnetic implant.
\*For the purpose of this protocol "chronic medical problems' is defined as any current condition not amenable to curative therapy and which requires long-term medical treatment and/or clinical monitoring.
Minimum Eligible Age
21 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
My-Le Nguyen, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Heart, Lung, and Blood Institute (NHLBI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Nguyen TT, Botello G, Sachdev V, Sidenko S, Ernst I, Waclawiw MA, Leitman SF, Rosing DR. Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. Am J Cardiol. 2006 Oct 1;98(7):954-9. doi: 10.1016/j.amjcard.2006.04.040. Epub 2006 Aug 15.
Reference Type
BACKGROUND
Shizukuda Y, Tripodi DJ, Smith KP, Arena R, Waclawiw MA, Rosing DR. Can we use heart rate recovery information generated by supine ergometry exercise? Am J Cardiol. 2006 Nov 1;98(9):1297-8. doi: 10.1016/j.amjcard.2006.07.009. Epub 2006 Aug 31. No abstract available.
Reference Type
BACKGROUND
Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Smith KP, Sachdev V, Birdsall CW, Sidenko S, Waclawiw MA, Leitman SF, Rosing DR. Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis. Am J Cardiol. 2006 Sep 1;98(5):694-8. doi: 10.1016/j.amjcard.2006.03.055. Epub 2006 Jul 7.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2003-H-0282.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03-H-0282
Identifier Type: -
Identifier Source: secondary_id
030282
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
NCT05742035
UNKNOWN
NA
Iron Overload in African Americans
NCT00001455
COMPLETED
Genes Influencing Iron Overload State
NCT01158794
COMPLETED
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients
NCT01398644
UNKNOWN
PHASE3
MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions.
NCT00629291
COMPLETED
Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency
NCT03079518
COMPLETED
PHASE2
Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity
NCT02619955
COMPLETED
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
NCT03218384
TERMINATED
PHASE2
T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients
NCT00520559
COMPLETED
"Iron Overload and Endocrinological Diseases"
NCT06137079
RECRUITING
Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
NCT01911871
COMPLETED
Hepcidin in Anemic Chronic Heart Failure (CHF) Patients
NCT00437866
COMPLETED
HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis
NCT01784939
COMPLETED
Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure
NCT01925703
COMPLETED
PHASE4
Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction
NCT03074591
COMPLETED
PHASE4
Out Come Study To Define Laboratory Parameters That Are Best Suited to Diagnose Functional Iron Deficiency
NCT00495781
COMPLETED
NA
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
NCT01810965
COMPLETED
NA
Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?
NCT01631708
COMPLETED
NA
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
NCT03203850
TERMINATED
PHASE2
IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure
NCT06542822
RECRUITING
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
NCT00000588
COMPLETED
PHASE2
Iron Replacement in Blood Donors
NCT00327067
COMPLETED
Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
NCT03036462
COMPLETED
PHASE4
Iron Deficiency in Acute Myocardial Infarction: Prevalence Pilot Study
NCT06457815
RECRUITING